40th Annual J.P. Morgan Healthcare Conference Presentation

Well-Positioned for Future Growth Technology leadership ▪ Expanding total addressable market: $8.1B High impact systems and consumable products for flexible manufacturing ■ ▪ Strong base business with additional gains from Gene Therapy and COVID programs ■ R&D engine for next-generation products ▪ Expanding manufacturing capacity ■ $620M-$630M in cash to support M&A, capital projects R REPLIGEN Growth Rates 2021e by Franchise 2021e figures above are based on 10/28/21 guidance FILTRATION ~125% ANALYTICS ~35% CHROMA 40%-45% PROTEINS 40%-45% 2024 Revenue Goal $1.0 Billion 16

View entire presentation